Reducing radiation successfully treats HPV-positive oropharynx cancers and minimizes side effects
- Date:
- December 26, 2016
- Source:
- Yale Cancer Center
- Summary:
- Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise. After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues. However, new clinical trial research shows reducing radiation for some patients with HPV-associated oropharyngeal squamous cell carcinomas can maintain high cure rates while sparing some of these late toxicities.
- Share:
Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise. After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues. However, new clinical trial research shows reducing radiation for some patients with HPV-associated oropharyngeal squamous cell carcinomas can maintain high cure rates while sparing some of these late toxicities.
"We found there are some patients have very high cure rates with reduced doses of radiation," said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee. "Radiation dose reduction resulted in significantly improved swallowing and nutritional status," she said.
The study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).
"Today, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx," said Dr. Burtness. "And while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence," said Dr. Burtness. "Younger patients may have to deal with these side effects for decades after cancer treatment. We want to help improve our patients' quality of life."
The study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery. Eligible patients received three courses of induction chemotherapy with the drugs cisplatin, paclitaxel, and cetuximab. Patients with good clinical response then received reduced radiation.
Study results also showed that patients who had a history of smoking less than 10 packs of cigarettes a year had a very high disease control compared with heavy smokers.
Other authors on the paper include: Shanthi Marur (Johns Hopkins Medicine) and Anthony Cmelak (Vanderbilt University).
Story Source:
Materials provided by Yale Cancer Center. Note: Content may be edited for style and length.
Journal Reference:
- Shanthi Marur, Shuli Li, Anthony J. Cmelak, Maura L. Gillison, Weiqiang J. Zhao, Robert L. Ferris, William H. Westra, Jill Gilbert, Julie E. Bauman, Lynne I. Wagner, David R. Trevarthen, Jahagirdar Balkrishna, Barbara A. Murphy, Nishant Agrawal, A. Dimitrios Colevas, Christine H. Chung, and Barbara Burtness. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology, 2016 DOI: 10.1200/JCO.2016.68.3300
Cite This Page: